The way to slow down the disease progression of Alzheimer’s patients can delay the onset of people with diseases that are not yet symptoms.
The results just published in clinical trials for experimental drugs targeting amyloid plaque accumulation suggest that brakes can be reduced if the brake is sufficiently taken early.
“This is now very optimistic because it can be the first clinical evidence to be prevented for those who are at risk of Alzheimer’s illness.” Say Washington University neurologist and senior author, Randal J. Batman.
“One day, we can delay millions of people with Alzheimer’s disease.”
This test includes dominantly inherited Alzheimer’s volunteers, which are caused by genes that increase the production of amyloid proteins. Mutations are only 1 %of all cases of Alzheimer’s case Development of conditions In their fifties, they are almost certain.
2012The study began with the potential of treatment based on the combination of two antibodies in slowing the progression of individual diseases with no or minor cognitive reduction.
however Step 3 clinical trials The lack of symptoms of the two groups showed that Gantenerumab, one of the drugs, caused dramatic improvements in the pathology itself.
Researchers, encouraged by clinical signs of the decrease in protein markers, continued to investigate whether the treatment of high doses could make a difference.
Participants with high -risk mutations were invited to maintain the test and receive the drug regardless of whether they were in the control group that had previously been placed.
Although the expansion itself has decreased as the clinical trials have not been established, the analysis of the influence of Gantenerumab has still been potential.
There was a risk that the symptoms were reduced by half of those who took the drug for both the test period and extension. The effect can be more dramatic. The risk of decreasing asymmetrical groups in mental health increases over age.
Over time, the comparison of those who have taken drugs since 2012 and those who have taken the drug for two years may still be much more likely to delay.
“Everyone in this study was destined to develop Alzheimer’s disease, and some of them were yet.” Say baton.
“What we know is that at least we can delay the development of the symptoms of Alzheimer’s disease and give people a healthier life.”
In this way, using antibodies is no risk. Gantenerumab and similar processing have been connected Small bleeding and swelling In rare situations, in the brain that can be fatal. There is also a microbled It is known to increase As Alzheimer’s progresses.
Other next-generation anti-amyloid therapy has been approved in the United States for individual treatment with Alzheimer’s symptoms, and potentially improved perceptions have been added to years of life.
Time will tell you whether people who expect nerve to fight for decades can be saved. But the signs that researchers are on the right way are increasingly positive.
This study has been published Lancet Neurology.
